TY  - JOUR
AU  - Pavlović, Marijana
AU  - Kahrović, Emira
AU  - Aranđelović, Sandra
AU  - Radulović, Siniša
AU  - Ilich, Predrag-Peter
AU  - Grgurić-Šipka, Sanja
AU  - Ljubijankić, Nevzeta
AU  - Žilić, Dijana
AU  - Jurec, Jurica
PY  - 2023
UR  - http://cherry.chem.bg.ac.rs/handle/123456789/5901
AB  - Novel ruthenium(III) complexes of general formula Na[
RuCl2(L1−3-N,O)2] where L(
1–3) denote deprotonated Schiff bases
(
HL1-HL3) derived from 5-substituted salicyladehyde and alkylamine (propyl- or butylamine) were prepared and characterized
based on elemental analysis, mass spectra, infrared, electron spin/paramagnetic resonance (ESR/EPR) spectroscopy,
and cyclovoltammetric study. Optimization of five isomers of complex C1 was done by DFT calculation. The interaction
of C1–C3 complexes with DNA (Deoxyribonucleic acid) and BSA (Bovine serum albumin) was investigated by electron
spectroscopy and fluorescence quenching. The cytotoxic activity of C1–C3 was investigated in a panel of four human cancer
cell lines (K562, A549, EA.hy926, MDA-MB-231) and one human non-tumor cell line (MRC-5). Complexes displayed an
apparent cytoselective profile, with IC50
values in the low micromolar range from 1.6 ± 0.3 to 23.0 ± 0.1 μM. Cisplatinresistant
triple-negative breast cancer cells MDA-MB-231 displayed the highest sensitivity to complexes, with Ru(III)
compound containing two chlorides and two deprotonated N-propyl-5-chloro-salicylidenimine (hereinafter C1) as the most
potent (
IC50 = 1.6 μM), and approximately ten times more active than cisplatin (
IC50 = 21.9 μM). MDA-MB-231 cells treated
for 24 h with C1 presented with apoptotic morphology, as seen by acridine orange/ethidium bromide staining, while 48 h of
treatment induced DNA fragmentation, and necrotic changes in cells, as seen by flow cytometry analysis. Drug-accumulation
study by inductively coupled plasma mass spectrometry (ICP-MS) demonstrated markedly higher intracellular accumulation
of C1 compared with cisplatin.
PB  - Springer
T2  - J. Biol. Inorg. Chem.
T1  - Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells
VL  - 28
SP  - 263
EP  - 284
DO  - 10.1007/s00775-023-01989-0
ER  - 

@article{
author = "Pavlović, Marijana and Kahrović, Emira and Aranđelović, Sandra and Radulović, Siniša and Ilich, Predrag-Peter and Grgurić-Šipka, Sanja and Ljubijankić, Nevzeta and Žilić, Dijana and Jurec, Jurica",
year = "2023",
abstract = "Novel ruthenium(III) complexes of general formula Na[
RuCl2(L1−3-N,O)2] where L(
1–3) denote deprotonated Schiff bases
(
HL1-HL3) derived from 5-substituted salicyladehyde and alkylamine (propyl- or butylamine) were prepared and characterized
based on elemental analysis, mass spectra, infrared, electron spin/paramagnetic resonance (ESR/EPR) spectroscopy,
and cyclovoltammetric study. Optimization of five isomers of complex C1 was done by DFT calculation. The interaction
of C1–C3 complexes with DNA (Deoxyribonucleic acid) and BSA (Bovine serum albumin) was investigated by electron
spectroscopy and fluorescence quenching. The cytotoxic activity of C1–C3 was investigated in a panel of four human cancer
cell lines (K562, A549, EA.hy926, MDA-MB-231) and one human non-tumor cell line (MRC-5). Complexes displayed an
apparent cytoselective profile, with IC50
values in the low micromolar range from 1.6 ± 0.3 to 23.0 ± 0.1 μM. Cisplatinresistant
triple-negative breast cancer cells MDA-MB-231 displayed the highest sensitivity to complexes, with Ru(III)
compound containing two chlorides and two deprotonated N-propyl-5-chloro-salicylidenimine (hereinafter C1) as the most
potent (
IC50 = 1.6 μM), and approximately ten times more active than cisplatin (
IC50 = 21.9 μM). MDA-MB-231 cells treated
for 24 h with C1 presented with apoptotic morphology, as seen by acridine orange/ethidium bromide staining, while 48 h of
treatment induced DNA fragmentation, and necrotic changes in cells, as seen by flow cytometry analysis. Drug-accumulation
study by inductively coupled plasma mass spectrometry (ICP-MS) demonstrated markedly higher intracellular accumulation
of C1 compared with cisplatin.",
publisher = "Springer",
journal = "J. Biol. Inorg. Chem.",
title = "Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells",
volume = "28",
pages = "263-284",
doi = "10.1007/s00775-023-01989-0"
}

Pavlović, M., Kahrović, E., Aranđelović, S., Radulović, S., Ilich, P., Grgurić-Šipka, S., Ljubijankić, N., Žilić, D.,& Jurec, J.. (2023). Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells. in J. Biol. Inorg. Chem.
Springer., 28, 263-284.
https://doi.org/10.1007/s00775-023-01989-0

Pavlović M, Kahrović E, Aranđelović S, Radulović S, Ilich P, Grgurić-Šipka S, Ljubijankić N, Žilić D, Jurec J. Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells. in J. Biol. Inorg. Chem.. 2023;28:263-284.
doi:10.1007/s00775-023-01989-0 .

Pavlović, Marijana, Kahrović, Emira, Aranđelović, Sandra, Radulović, Siniša, Ilich, Predrag-Peter, Grgurić-Šipka, Sanja, Ljubijankić, Nevzeta, Žilić, Dijana, Jurec, Jurica, "Tumor Selective Ru(III) Schiff Bases Complexes with Strong In Vitro Activity Toward Cisplatin-Resistant MDA-MB-231 Breast Cancer Cells" in J. Biol. Inorg. Chem., 28 (2023):263-284,
https://doi.org/10.1007/s00775-023-01989-0 . .